Vulvar cancer

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
월요일, 11월 13, 2023
Theta, Inner circle, Georgetown University, Brown University, Woman, Oncology nursing, Associate, Reproductive Sciences, Research, Radiation, Cervical cancer, Gynecologic Oncology (journal), Overlook Medical Center, Pathology, National Cancer Institute, Roswell Park, Mount Sinai School, Women's studies, Multimedia, Professional, Fellow, Thomas Jefferson University, Vaginal cancer, Medication, Health, Alpert Medical School, Vulvar cancer, ABOG, Uterine cancer, Exceptional Women in Publishing, Ovarian cancer, MD, Japanese Cancer Association, FACOG, Delta Sigma, Women's health, Atlantic Women's Colleges Conference, Carol, Volunteering, Flexner Report, Estate (law), Biology, Education, Birth control, Science, Gynaecology, Medicine, Cancer, New York (magazine), Neuroscience, Obstetrics

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

The silence around vulval cancer means people are missing the signs that they have it

Retrieved on: 
수요일, 9월 27, 2023
Panic, Vagina, Tissue, Lymphedema, University, Awareness, Penis, Cancer, Quality of life, Cancer Research UK, Woman, Leg, Vulvectomy, Breast self-examination, Embarrassment, Incidence, Shame, Cervical cancer, Clitoris, Manchester, Menopause, Neoplasm, HPV, Diagnosis, VIN, Vulvar cancer, Imagination, Rest, Human papillomavirus infection, Dvin, Skin, Female, Great Wall of China, Birth control, Dietary supplement, Vaccine, Glass wool, Interior design, Vulva

Most people have heard of cervical, ovarian, and perhaps womb cancer, but there is one gynaecological cancer that is seldom mentioned: vulval cancer.

Key Points: 
  • Most people have heard of cervical, ovarian, and perhaps womb cancer, but there is one gynaecological cancer that is seldom mentioned: vulval cancer.
  • According to Cancer Research UK, 69% of vulval cancers are considered preventable.
  • In late-stage cancer, the treatment may be devastating and in extreme cases can involve removing the entire vulva, so increasing awareness is vital.
  • The other main condition linked to vulval cancer is LS, a chronic skin condition which typically causes intense itching and white or ashy patches.

Delayed diagnosis

    • In one Danish study comparing the diagnosis time of all gynaecological cancers, vulval cancer was found to have the longest delay.
    • If you are concerned you have symptoms of vulval cancer or LS, you may need to insist on being examined.
    • To this end, the University of Manchester has produced a resource to teach women how to do a vulval self-examination.
    • Resources such as the Great Wall of Vulva can help women understand that vulvas come in all shapes and sizes.

Treatment for vulval cancer

    • However, treatment for later stage vulval cancer can be brutal.
    • In England, vulval cancer incidence rates are 74% higher in the most deprived groups.
    • Increased awareness could save some women from being diagnosed with later stage vulval cancer and improve survival rates.
    • We should be taking vulval itching and pain seriously, talking about vulval cancer and emphasising the importance of the HPV vaccine.

Human Papillomavirus Vaccine Research Report 2023: Highly Effective HPV Vaccines Target Major Cancer-Causing Strains - Global Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
화요일, 9월 12, 2023
Infectious Diseases, Pharmaceutical, Health, Vaccine, The central science, Infection, Anal cancer, Prevalence, Vagina, PAHO, Pharynx, Human papillomavirus infection, Vulvar cancer, Woman, Research, UNICEF, Pan American Health Organization, Government, Competition, CDC, Organization, Market, Death, Cervical cancer, Developed country, Korea Disease Control and Prevention Agency, HPV, Growth, WHO

According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe.

Key Points: 
  • According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe.
  • Upsurge in the cases of Human Papillomavirus related diseases in different organs such as the anal, oropharynx, and genital parts has significantly raised the demand for Human Papillomavirus vaccines, thereby creating lucrative opportunities for market growth.
  • This has, in turn, increased the research and development activities and products launched related to human papillomavirus vaccine.
  • For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer.

Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

Retrieved on: 
화요일, 9월 5, 2023
Research, Teens, Infectious Diseases, Children, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, MSD, Hypersensitivity, CIN, Male, Female, Pediatrics, Allergy, Life, Vaccination, CIN1, Human papillomavirus infection, Cancer, MRK, Vulvar cancer, Woman, Head, Month, AIS, Vulvectomy, Merck & Co., CDC, Incidence, Death, PIN, Anal cancer, Cervical cancer, Wart, Vain, Vaginal intraepithelial neoplasia, HPV, VIN, Cervical intraepithelial neoplasia, Anus, NYSE, Disease, Vaccine, Birth control, Recombinant, Merck

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.

Key Points: 
  • The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • As part of the primary objective of immunogenicity, data showed sustained HPV-antibody responses at 10 years after the third dose in boys and girls.
  • With the exception of cervical cancer, there is no routinely recommended screening for the detection of HPV-related cancers.

Move4Her Returns Empowering Participants in the Fight to Eradicate Gynecologic Cancers

Retrieved on: 
목요일, 6월 15, 2023
Society, SGO, Education, Vulvar cancer, FWC, National Press Club (United States), Press club, Gynecologic Oncology (journal), Research, Movement, EMLL 55th Anniversary Show, Organization, Society of Gynecologic Oncology, MD, Cancer, Diagnosis, Health, Message, Birth control

CHICAGO, June 15, 2023 /PRNewswire/ -- The Foundation for Women's Cancer (FWC) is pleased to announce the return of Move4Her, now bigger and better than ever! Embarking on its fourth consecutive year, Move4Her stands at the forefront of the FWC's mission to power research, awareness and education surrounding the five gynecologic (gyn) cancers – cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer.

Key Points: 
  • Embarking on its fourth consecutive year, Move4Her stands at the forefront of the FWC's mission to power research, awareness and education surrounding the five gynecologic (gyn) cancers – cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer.
  • Move4Her encourages participants to dedicate five minutes each day to their fitness and fundraising mission.
  • Taking steps to protect your health, and to connect with others by sharing stories and experiences, Move4Her participants will power a much-needed movement.
  • Throughout the year new tools and resources will be released to support individuals, teams and local organizations participating in Move4Her.

FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors

Retrieved on: 
수요일, 3월 29, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histology, Hepatocellular carcinoma, Cohort, DOR, RECIST, Carcinoma, Head, Vaginal cancer, Patient, Division, Mesothelioma, Immunohistochemistry, NYSE, Prostate cancer, MMR, Glomus tumor, Oxaliplatin, MRK, Toxicity, Research, Brain, Nephritis, Merck & Co., Sarcoma, HIV disease progression rates, Cervical cancer, Polymerase chain reaction, MSI, Memorial Sloan Kettering Cancer Center, MSI-H, Pancreatic cancer, Hepatitis, Vulvar cancer, Cancer, Pneumonitis, Bladder cancer, Cholangiocarcinoma, Immunotherapy, Autoimmune disease, Irinotecan, Testicular cancer, Ovarian cancer, Thyroid cancer, ORR, Hematopoietic stem cell transplantation, Anal cancer, Colitis, Endometrial cancer, Immunosuppression, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Breast cancer, Pharmaceutical industry, Vaccine, Merck

This marks the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type.

Key Points: 
  • This marks the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type.
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • Patients were either prospectively enrolled with MSI-H/dMMR tumors (Cohort K) or retrospectively identified in one of 10 solid tumor cohorts (Cohorts A-J).
  • In KEYNOTE-158 and KEYNOTE-164, the median duration of exposure to KEYTRUDA was 6.2 months (range, 1 day to 53.5 months).

PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal

Retrieved on: 
수요일, 3월 1, 2023
Safety, Immunotherapy, Neck, Vulvar cancer, Cancer, Patient, Survival, PDS, NK, PDSB, CD8, Research, NKT, Interleukin, Trial of the century, Serum, Interleukin 12, Head, Bangladesh Technical Education Board, Neoplasm, IL-12, Biotechnology, Infection, NCI, Vaccine

The clinical study assessed immune changes in relation to the dose level and dosing schedule of PDS0301 (NHS-IL12), a novel investigational fusion protein consisting of a tumor-targeting antibody conjugated to Interleukin 12 (IL-12).

Key Points: 
  • The clinical study assessed immune changes in relation to the dose level and dosing schedule of PDS0301 (NHS-IL12), a novel investigational fusion protein consisting of a tumor-targeting antibody conjugated to Interleukin 12 (IL-12).
  • The study also evaluated the correlation of several treatment-related immunological changes with clinical responses.
  • “Importantly, this study appears to demonstrate the safety and tolerability of biologically active doses of PDS0301 and reports increases in specific immune cells that were associated with PDS0301 administration and improved clinical outcomes."
  • The publication also summarizes clinical results from a study combining PDS0301, with a checkpoint inhibitor and PDS0101, PDS Biotech’s HPV-targeted immunotherapy that has been shown to promote induction of multifunctional, tumor-infiltrating killer T-cells.

Insights on Global Cancer Vaccines Market Size & Share Projected to Hit at USD 19.27 Billion and Rise at a CAGR of 14.75% By 2030: Industry Trends, Demand, Value, Analysis & Forecast Report | Facts and Factors

Retrieved on: 
화요일, 2월 7, 2023
National Center for Immunization and Respiratory Diseases, Prostate, Brain, Vaccine, Spinal cord, Woman, Smoking, Government, Hospital, Blood, White blood cell, Cancer, Breast, HPV, Rectum, Leukemia, Immunity, Projection, Tissue, Lymphoma, Radiation, Bone marrow, Lung, Patient, Cancer research, Skin, Bladder cancer, Prostate cancer, Partner (business rank), CNS, Cartilage, Risk, USD, Immune system, Carcinoma, Lung cancer, Vulvar cancer, Central nervous system, Cervical cancer, Classification, Medical imaging, Pharmaceutical industry

The global cancer vaccines market is projected to grow due to the increasing number of types of cancer and the population suffering from such cancers.

Key Points: 
  • The global cancer vaccines market is projected to grow due to the increasing number of types of cancer and the population suffering from such cancers.
  • Based on indication, the global market is divided into bladder cancer, cervical cancer, lung cancer, prostate cancer, and others.
  • List of Key Players in Cancer Vaccines Market:
    Key questions answered in this report:
    What are the growth rate forecast and market size for CANCER VACCINES Market?
  • How can I receive a free copy of the CANCER VACCINES Market sample report and company profiles?

Insights on Global Cancer Vaccines Market Size & Share Projected to Hit at USD 19.27 Billion and Rise at a CAGR of 14.75% By 2030: Industry Trends, Demand, Value, Analysis & Forecast Report | Facts and Factors

Retrieved on: 
화요일, 2월 7, 2023
National Center for Immunization and Respiratory Diseases, Prostate, Brain, Vaccine, Spinal cord, Woman, Smoking, Government, Hospital, Blood, White blood cell, Cancer, Breast, HPV, Rectum, Leukemia, Immunity, Projection, Tissue, Lymphoma, Radiation, Bone marrow, Lung, Patient, Cancer research, Skin, Bladder cancer, Prostate cancer, Partner (business rank), CNS, Cartilage, Risk, USD, Immune system, Carcinoma, Lung cancer, Vulvar cancer, Central nervous system, Cervical cancer, Classification, Medical imaging, Pharmaceutical industry

The global cancer vaccines market is projected to grow due to the increasing number of types of cancer and the population suffering from such cancers.

Key Points: 
  • The global cancer vaccines market is projected to grow due to the increasing number of types of cancer and the population suffering from such cancers.
  • Based on indication, the global market is divided into bladder cancer, cervical cancer, lung cancer, prostate cancer, and others.
  • List of Key Players in Cancer Vaccines Market:
    Key questions answered in this report:
    What are the growth rate forecast and market size for CANCER VACCINES Market?
  • How can I receive a free copy of the CANCER VACCINES Market sample report and company profiles?

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

Retrieved on: 
화요일, 1월 3, 2023
Cancer, Standard of care, OS, International, Head, Food, Infection, Vulvar cancer, Merck, PDS, Platinum, Biotechnology, Neoplasm, Patient, Merck KGaA v. Integra Lifesciences I, Ltd., CPI-0610, PD-L1, FDA, Webcast, IL-12, Food and Drug Administration Amendments Act of 2007, Merck Group, Longevity, PDSB, National Cancer Institute, Neck, TGF, PARK, Palladium, Pharmaceutical industry, CPI

FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor-targeting IL-12 fusion protein M9241 (formerly known as NHS-IL12), which will join the pipeline as PDS0301. M9241 appears to enhance the proliferation, potency and longevity of T cells in the tumor. The combination of Versamune® and IL-12 is patented by PDS Biotech and is designed to overcome tumor immune suppression utilizing a different mechanism from checkpoint inhibitors.

Key Points: 
  • Under the terms of the agreement, PDS Biotech will receive from Merck KGaA, Darmstadt, Germany an exclusive license to M9241.
  • PDS Biotech will assume responsibility for future development, commercialization, and manufacturing of M9241.
  • “We are pleased to have partnered with Merck KGaA, Darmstadt, Germany to advance the development of M9241, a highly innovative cytokine therapy,” said Dr. Frank Bedu-Addo, PDS Biotech CEO.
  • “Under the licensing arrangement between Merck KGaA, Darmstadt, Germany and PDS Biotech, assumption of an equity stake by Merck KGaA, Darmstadt, Germany in PDS Biotech further confirms the potential of the Versamune® platform and the data generated to date with this combination therapy.